Affymetrix (NASDAQ:AFFX) announces that eBioscience, an
Affymetrix business, and Binding Site Group Ltd. have entered into
a multi-year distribution agreement. Under this agreement, The
Binding Site has been granted the exclusive rights to distribute
the eBioscience clinical flow cytometry reagents (ASR & CE
marked) in the clinical care market, including hospitals and
reference labs.
eBioscience, a world leader in immunology and oncology research
reagents, offers one of the world’s largest selections of
antibodies, ELISAs, multiplex solutions, and proteins for
immunology, oncology, cell biology, stem cell biology, and clinical
markets.
The Binding Site is a world-wide in vitro diagnostic (IVD)
supplier of special protein reagents and instruments, with a long
history of success developing novel products to aid in the
diagnosis and monitoring of monoclonal gammopathies such as
multiple myeloma and other leukemia.
“Our best-in-class full ASR and CE designated immunology and
oncology antibody portfolio is a natural complement to the
expertise of The Binding Site,” said Dara Grantham Wright, Senior
Vice President & General Manager of the eBioscience business at
Affymetrix. “Together we now provide an outstanding solution for
clinicians to improve identification, interpretation, and
management of clinical hematological malignancies. With this
agreement, we strengthen our emphasis on addressing the needs of
the growing cancer diagnostics market.”
“Our vision is to lead the way in specialized medical
diagnostics, as we do, for example, in multiple myeloma and
immunodeficiency,” said Charles de Rohan, Chief Executive of The
Binding Site Group. “We are delighted to be joining forces with
eBioscience, one of the most progressive providers of flow
cytometry reagents. With our excellent direct sales and support
coverage, we look forward to providing more clinical laboratories
with this comprehensive portfolio of innovative products.”
“This partnership broadens our cancer-based diagnostic portfolio
and allows us to provide a more comprehensive product offering to
our customers. We will be better positioned to meet the needs of
clinicians by capitalizing on eBioscience’s long history of quality
flow cytometry reagents and our commitment to cancer diagnostics,”
said Doug Kurth, President of The Binding Site Inc.
The Binding Site started servicing customers in the United
States on Dec. 1, 2014 and will start to service customers outside
of the United States on Feb. 15, 2015.
About Binding Site Group Ltd.
Headquartered in Birmingham, UK, Binding Site is a Specialist
Protein company committed to the research, development, manufacture
and distribution of innovative, immunodiagnostic assays for the
global laboratory market. By utilizing its specialized expertise in
antibody specificity technology, Binding Site gives clinicians and
laboratory staff the tools to significantly improve diagnosis and
management of those patients with specific cancers and immune
disorders.
Binding Site manufactures a wide range of innovative products
for plasma protein analysis such as Freelite® and
Hevylite®, novel and highly significant tumor markers
increasingly used for the diagnosis and monitoring of Multiple
Myeloma, a cancer of cells in the bone marrow.
Binding Site is a market leader in the development of products
for the investigation of Primary Immunodeficiency Disease (PID),
disorders in which part of the body's immune system is missing or
not functioning correctly.
Binding Site markets the SPAPLUS®, a cost effective, reliable
and easy to use analyzer offering a comprehensive menu of special
proteins. The SPAPLUS complements the automated chemistry line as
well as the special chemistry testing laboratory.
Binding Site is committed to disease state management and
clinical practice guidelines. Binding Site's team of medical
professionals have the exceptional expertise and practical
experience to assist with technical and clinical education and
training, from validation to implementation and beyond, giving
clinicians and laboratory staff the tools to significantly improve
diagnosis and management of patients.
For more information about Binding Site, please visit
www.bindingsite.com.
About eBioscience:
Established in San Diego, CA in 1999, eBioscience is a world
leader in immunology and oncology flow cytometry reagents.
eBioscience, was acquired by Affymetrix in 2012 and offers one of
the world’s largest selections of antibodies, ELISAs, and proteins
for life science research and diagnostics.
eBioscience is an industry leader in reagent offerings for
multicolor flow cytometry and immunoassay applications. We provide
a comprehensive and innovative portfolio of reagents and kits for
the immunology, oncology, cell biology, stem cell biology, and
diagnostic markets.
For more information about eBioscience, please visit
www.ebioscience.com.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness. The
Company provides leadership and support, partnering with customers
in pharmaceutical, diagnostic, and biotechnology companies, as well
as leading academic, government, and non-profit research institutes
in their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
65,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, Ohio,
San Diego, Vienna, and Singapore. The Company has about 1,100
employees worldwide and maintains sales and distribution operations
across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2013, and other SEC reports for subsequent
quarterly periods.
AffymetrixMedia
contact:Mindy Lee-Olsen, +1 408-731-5523Vice President,
Marketing Servicesmindy_lee-olsen@affymetrix.comInvestor
Contact:Doug Farrell, +1 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.comorBinding Site Group Ltd.Claire Perkins, +44
(0)121-456-9596Manager, Marketing
Communicationsclaire.perkins@bindingsite.co.uk
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024
